Catherine Skari

Live Webinar on Thalassemia: Advances in 2021 with Dr M.D. Cappellini

The past decade has witnessed path-breaking advances with regard to novel therapeutic approaches of thalassaemia and, most significantly, phenomenal developments…

Read More »

Clinical Trials Update: The June 2021 Edition

TIF provides you with comprehensive and up-to-date information on developing drugs and therapies for thalassaemia and sickle cell disease (SCD)…

Read More »

NTS’s President & Vice President Meet With Iraqi Government Officials To Discuss Thalassaemia Prevention National Programme

In response to the invitation of the Prime Minister’s Advisors Authority to Mr. Thaer Ibrahim Al-Taei, President of the Thalassemia…

Read More »

The June Update: TIF’s Guide On COVID-19 Vaccinations & Therapeutic Drugs

As vaccination rates are slowing in the US and Europe, the spread of the Delta coronavirus variants causes growing concerns…

Read More »

It’s Here: The 4th Edition Of TIF Guidelines For The Management of TDT

TIF, its Board of Directors, and its International Scientific Advisory Board proudly present the 4th Edition of the Federation’s most…

Read More »

Guidelines for the Management of Transfusion-Dependent Thalassaemia (4th edition – Version 2.0)

Maria Domenica Cappellini, MD FACP Farmakis Dimitrios, MD, PhD, FESC Porter John, MBBS, MD, MPH, FRCP Ali T. Taher, MD,…

Read More »

PYRUVATE KINASE DEFICIENCY | Agios Submits New Drug Application To FDA For Mitapivat

“With this NDA filing, we are poised to deliver the first potentially disease-modifying therapy for people with PK deficiency, a…

Read More »

TIF Is Actively Participating In The 26th EHA Annual Congress

TIF is excited to be participating in the 26th EHA Annual Congress, held this year virtually on 09 – 17…

Read More »

TIF Proudly Supports World Blood Donor Day 2021

June 14 marks World Blood Donor Day 2021. World Blood Donor Day (WBDD) is a very special occasion dedicated to…

Read More »

Bluebirdbio Announces The Lifting Of FDA Clinical Hold for Sickle Cell Disease And β-Thalassaemia Studies

bluebird bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical holds on the…

Read More »